QUOTED. Jan. 18, 2019. George Savage.
Executive Summary
Proteus Digital Health announced a new partnership with Minneapolis-based Fairview Health Services and the University of Minnesota Health to prescribe "digital capecitabine," encapsulating the common chemotherapy drug with Proteus' sensor, to colorectal cancer patients. The goal is to achieve medication adherence, leading to enhanced treatment and outcomes, through home-based monitoring. See what George Savage, Proteus' co-founder and chief medical officer, had to say about the new digital oncology program here.
"What we find in the real world is that most patients aren't able to tolerate the (full eight cycles of chemotherapy) due to adverse events and other issues. By adding digital feedback to the physician and to the patient, we're hoping to support the patients in taking the med appropriately. The tool can help the physician "see how the patient is doing in a more granular way to hopefully prevent these sorts of things that would lead to hospital admission and cessation of the chemotherapy early."—George Savage, chief medical officer, Proteus Digital Health
- Find out more: Bringing A Digital Pill to Oncology: Proteus Partners With Health System To Prescribe Sensor-Enabled Chemotherapy
Click here for a free trial of Medtech Insight